All articles tagged with #obesity drug
Eli Lilly's experimental obesity drug, eloralintide, shows promising results in mid-stage trials, with significant weight loss and improved health markers, leading to plans for late-stage trials and potential as an alternative to existing therapies.
A study published in The Lancet found that Wegovy, an obesity drug, reduces the risk of major heart issues beyond just weight loss, with only about a third of the benefits explained by waist size reduction, leaving the exact protective mechanism still unknown.
Pfizer is acquiring Metsera for up to $7.3 billion to strengthen its position in the booming obesity drug market, focusing on innovative oral and injectable treatments, amid previous setbacks in its obesity drug development.
Eli Lilly's stock dropped 14% after its obesity pill, orforglipron, underperformed expectations in weight loss results, trailing behind competitors like Novo Nordisk, leading to concerns about rising competition and a potential impact on sales forecasts, despite the company's overall strong earnings and sales outlook.
Novo Nordisk's stock fell 3.8% after the company cut its full-year outlook, citing concerns over its obesity drug franchise led by semaglutide, causing investor worries and a continued decline in share price.
Novo Nordisk has lowered its sales forecast for the obesity drug Wegovy due to increased competition from compounded versions made by pharmacies, which are not FDA-approved but are legally customized for individual patients. The company is taking legal action to address this issue and has announced a new CEO, Maziar Mike Doustdar. Despite efforts to sell Wegovy directly to consumers, sales through cash channels have been lower than expected, impacting the company's stock.
Amgen's obesity drug MariTide showed significant weight loss in a Phase 2 trial but had high side effects and discontinuation rates, prompting the company to plan a slower dosing schedule for future testing.
Shares of Novo Nordisk fell up to 3.5% after trial data for its experimental obesity drug CagriSema raised investor concerns about its competitiveness against Eli Lilly, with questions about tolerability and market timing impacting investor confidence amid ongoing competition in the obesity market.
Eli Lilly's experimental obesity drug, eloralintide, showed promising results in early trials, with some patients losing over 11% of their body weight in 12 weeks, and the drug appears to be safe and effective, potentially serving as a successor or complement to existing obesity treatments like tirzepatide.
Eli Lilly's obesity drug has outperformed a rival in a direct clinical trial, potentially boosting the company's market position. Jim Cramer discusses the implications for Eli Lilly's stock, suggesting potential growth opportunities following the trial results.
Amgen's stock plummeted 12% after its obesity drug, MariTide, showed comparable results to Eli Lilly's Zepbound in weight loss efficacy but had a higher dropout rate due to side effects. While patients lost about 20% of their body weight with less frequent dosing, 11% discontinued due to gastrointestinal issues, compared to 7% for Zepbound. The market reacted negatively despite the drug meeting expectations, highlighting the competitive nature of the weight-loss drug market.
Novo Nordisk has launched its obesity drug Wegovy in China at a significantly lower price than in the US, marking a strategic move to capture a growing market. The first prescription was issued at Shanghai's Zhongshan Hospital.
Shares of Novo Nordisk and Eli Lilly fell after Roche announced promising early-stage trial data for its new obesity drug candidate, CT-996, which showed significant weight loss in obese patients. Roche's shares rose, while other companies in the obesity treatment market, including Zealand Pharma, also saw declines. Roche's new drug could offer a competitive alternative to injectable treatments, though it may take years to become widely available.
Eli Lilly reported that its obesity drug tirzepatide, or Zepbound, showed promising results in reducing obstructive sleep apnea in overweight or obese individuals, with an average of about 30 fewer apnea episodes per hour. The findings from yearlong clinical trials could provide a new treatment option for the 20 million Americans diagnosed with moderate to severe obstructive sleep apnea, potentially reducing their risk for associated health issues. While the detailed results are yet to be published, experts not affiliated with the company are encouraged by the summary and look forward to more comprehensive data at the American Diabetes Association’s 84th Scientific Sessions in June.
Eli Lilly's obesity drug Zepbound has shown positive results in treating obstructive sleep apnea (OSA) in a Phase 3 study, potentially positioning it as the first approved treatment for OSA. Patients taking Zepbound experienced a significant reduction in the apnea-hypopnea index compared to those on a placebo, indicating its potential to address breathing interruptions during sleep in individuals with obesity.